Frederick Klauschen
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Health Informatics top 0.2%
Papers in
-
- Cancer Genomics and Diagnostics 61
- Oncology 71
- Cancer Immunotherapy and Biomarkers 24
- Co-authors
- Klaus- Robert Müller (18 shared papers)Grégoire Montavon (7 shared papers)Alexander Binder (3 shared papers)Wojciech Samek (3 shared papers)Sebastian Bach (1 shared paper)Ronald N. Germain (10 shared papers)Carsten Denkert (32 shared papers)Jan Budczies (30 shared papers)
- Journals
- European Journal of Cancer (10 papers)Genes Chromosomes and Cancer (7 papers)Oncotarget (6 papers)Nature Communications (6 papers)Annals of Oncology (6 papers)
- Partner nations
- GermanyUnited StatesFrance
In The Last Decade
Frederick Klauschen
239 papers receiving 19.5k citations
Frederick Klauschen's Hit Papers
Peers
Comparison fields: 5 of 197
- Oncology 6.5k
- Health Informatics 328
- Cancer Research 3.0k
- Immunology 4.2k
- Biophysics 527
Countries citing papers authored by Frederick Klauschen
This map shows the geographic impact of Frederick Klauschen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frederick Klauschen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frederick Klauschen more than expected).
Fields of papers citing papers by Frederick Klauschen
This network shows the impact of papers produced by Frederick Klauschen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frederick Klauschen. The network helps show where Frederick Klauschen may publish in the future.
Co-authors
The 25 scholars most cited alongside Frederick Klauschen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 253 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | On Pixel-Wise Explanations for Non-Linear Classifier Decisions by Layer-Wise Relevance Propagation Hit paper breakdown → | 2015 | 3144 |
| 2 | The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 Hit paper breakdown → | 2014 | 2466 |
| 3 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy Hit paper breakdown → | 2017 | 1666 |
| 4 | Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization Hit paper breakdown → | 2012 | 1047 |
| 5 | Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers Hit paper breakdown → | 2014 | 868 |
| 6 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors Hit paper breakdown → | 2017 | 629 |
| 7 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research Hit paper breakdown → | 2017 | 553 |
| 8 | 2008 | 512 | |
| 9 | 2009 | 446 | |
| 10 | 2013 | 315 | |
| 11 | 2017 | 277 | |
| 12 | 2015 | 274 | |
| 13 | 2016 | 238 | |
| 14 | 2013 | 235 | |
| 15 | 2014 | 233 | |
| 16 | 2014 | 201 | |
| 17 | 2012 | 192 | |
| 18 | 2021 | 192 | |
| 19 | 2008 | 181 | |
| 20 | 2021 | 162 |
About Frederick Klauschen
Frederick Klauschen is a scholar working on Cancer Research, Oncology, Immunology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 253 papers that have together received 19.9k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (61 papers), Cancer Immunotherapy and Biomarkers (24 papers), Lung Cancer Treatments and Mutations (24 papers), Genetic factors in colorectal cancer (20 papers), Immunotherapy and Immune Responses (16 papers), Immune Cell Function and Interaction (15 papers), AI in cancer detection (14 papers) and T-cell and B-cell Immunology (14 papers). The work is most often cited by research in Oncology (6.5k citations), Health Informatics (328 citations), Cancer Research (3.0k citations), Immunology (4.2k citations) and Biophysics (527 citations). Frederick Klauschen has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Klaus- Robert Müller, Grégoire Montavon, Alexander Binder, Wojciech Samek, Sebastian Bach, Ronald N. Germain, Carsten Denkert, Jan Budczies, Albrecht Stenzinger and Balázs Győrffy. Their work appears in journals such as European Journal of Cancer, Genes Chromosomes and Cancer, Oncotarget, Nature Communications and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.